Gretchen Shull, MD
Endocrinology, Diabetes & Metabolism · Joplin, MONPI 1689621336
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,784 of the $5,319 with a category attached, or 71.1%. 28 manufacturers reported payments, led by Amgen at 33.1% of the total. 2025 is the largest year on record at $1,650, 3.6 times the $462 reported in 2019.
Across 221 payments — averaging $24.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$2K
- Novo Nordisk$967
- Dexcom, Inc.$476
- Abbott$335
- Boehringer Ingelheim$219
- Sanofi-aventis U.S. LLC$196
- plus $1K from 22 others
What the payments were for
- Speaking & faculty fees$1,40026%
- Food & beverage$3,78471%
- Education$1353%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 22 | $1,759 |
| Novo Nordisk | 60 | $967 |
| Dexcom, Inc. | 29 | $476 |
| Abbott | 15 | $335 |
| Boehringer Ingelheim | 14 | $219 |
| Sanofi-aventis U.S. LLC | 10 | $196 |
| Cequr Corporation | 2 | $131 |
| Bayer | 8 | $125 |
| Radius Health, Inc. | 6 | $125 |
| Antares Pharma, Inc. | 7 | $118 |
| AstraZeneca | 6 | $116 |
| Insulet Corporation | 3 | $96 |
| Lilly USA, LLC | 6 | $95 |
| Tandem Diabetes Care, Inc. | 6 | $92 |
| Medtronic(2 entities) | 5 | $78 |
| Ascendis Pharma Endocrinology Inc | 3 | $67 |
| Novartis | 3 | $61 |
| BETA Bionics, Inc. | 3 | $54 |
| Neurocrine Biosciences, Inc. | 2 | $46 |
| AbbVie | 2 | $40 |
| Valeritas, Inc. | 2 | $28 |
| Sequel Med Tech, LLC | 1 | $19 |
| Kyowa Kirin, Inc. | 1 | $17 |
| Shire North American Group Inc | 1 | $16 |
| Amneal Pharmaceuticals LLC | 1 | $14 |
| Merck | 1 | $12 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
| Clarus Therapeutics Inc. | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEPEZZA$1,400
- DEXCOM G7 GSS (161)$127
- CeQur Simplicity$114
How this compares
$5,319 in reported general payments places this provider in the 70th percentile of 182 endocrinology, diabetes & metabolism providers in Missouri.
See all endocrinology, diabetes & metabolism providers in Missouri →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 220 | $301,708 |
| JardianceEmpagliflozin | 99 | $99,535 |
| TrulicityDulaglutide | 67 | $88,202 |
| MounjaroTirzepatide | 59 | $81,264 |
| Tresiba Flextouch U-200Insulin Degludec | 34 | $73,741 |
| JanuviaSitagliptin Phosphate | 49 | $46,823 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 49 | $38,767 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 52 | $37,234 |
| Tresiba Flextouch U-100Insulin Degludec | 60 | $35,950 |
| FarxigaDapagliflozin Propanediol | 38 | $35,421 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 39 | $33,935 |
| RybelsusSemaglutide | 16 | $22,849 |
| XyostedTestosterone Enanthate | 37 | $22,812 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 47 | $21,115 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $20,187 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $967 | $330,440250 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Insulin Lispro | $95 | $172,082155 claims |
| Boehringer IngelheimJardiance | $219 | $99,53599 claims |
| MerckJanuvia | $12 | $46,82349 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $196 | $40,43974 claims |
| AstraZenecaFarxiga | $116 | $35,42138 claims |
| Antares Pharma, Inc.Xyosted | $118 | $22,81237 claims |
| AbbVieSynthroid | $40 | $11,973155 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $14 | $7,076770 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 182 endocrinology, diabetes & metabolism providers in Missouri.
Other endocrinology, diabetes & metabolism in Joplin
- Ralph DudaSpringfield$644K
- Karen Chang-ChenChesterfield$640K
- Alan RaubaJefferson City$594K
- Jerome ThurmanSaint Charles$312K
- Janet McGillSaint Louis$212K
- Megan WoodSt. Louis$207K
- Ralph OiknineChesterfield$144K
- Jonben SvobodaSpringfield$142K
- James BonucchiSpringfield$128K
- Christopher CaseJefferson City$121K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.